Stephen M. Ansell, MD, PhD

Key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.

Stephen M. Ansell, MD, PhD, highlights several emerging therapeutics that have the potential to better harness the immune system in patients with lymphoma subtypes.

Stephen M. Ansell, MD, PhD, discusses the investigation of loncastuximab tesirine in the phase 2 LOTIS-2 trial in relapsed/refractory diffuse large B-cell lymphoma.

Stephen M. Ansell, MD, PhD, discusses the evolving treatment landscape in diffuse large B-cell lymphoma.

Stephen M. Ansell, MD, PhD, discusses incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.

Stephen M. Ansell, MD, PhD, discusses challenges with positron emission tomography scans in patients with Hodgkin lymphoma.

Stephen M. Ansell, MD, PhD, discusses the role of positron emission tomography scans in patients with Hodgkin lymphoma.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the role of PD-1 blockade in lymphoma.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses strategies addressing immune evasion in patients with lymphoma.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses immune invasion in lymphoma.

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses difficult challenges to overcome in the landscape of mantle cell lymphoma (MCL).

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the possibility of blending immunotherapy agents with chimeric antigen receptor (CAR) T-cell therapy across lymphoma populations.

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses promising combinations in the pipeline for mantle cell lymphoma (MCL).

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses some of the recent therapeutic advancements that have been reported in the field of mantle cell lymphoma (MCL).

Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses studies exploring PD-1 inhibitors in Hodgkin lymphoma, specifically the CheckMate-039 trial.